About this trial
Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed.
At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3).
Disqualifiers
primary hypersomnia or hypersomnia due to shift work, sleep deprivation and other sleep rhythm disturbances;
excessive sleep due to drug abuse;
suffering from Parkinson's disease, Alzheimer's disease and other nervous system diseases and mental diseases;
complicated with heart, lung, liver, kidney, blood endocrine system and other basic diseases, or acute chronic infection in a short period of time;
Trial population
Patients with narcolepsy
Trial design
Case-control
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
To screen potential molecular markers related to the biological characteristics and prognosis of narcolepsy.
1. omics analysis of metabolic mechanisms related to narcolepsy and screening of co-enriched pathways. To screen potential molecular markers related to the biological characteristics and prognosis of narcolepsy. 2. To study the body fluid and imaging characteristics of narcolepsy patients.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.